JP7242650B2 - ヒト化C1q複合体を発現する非ヒト動物 - Google Patents

ヒト化C1q複合体を発現する非ヒト動物 Download PDF

Info

Publication number
JP7242650B2
JP7242650B2 JP2020518013A JP2020518013A JP7242650B2 JP 7242650 B2 JP7242650 B2 JP 7242650B2 JP 2020518013 A JP2020518013 A JP 2020518013A JP 2020518013 A JP2020518013 A JP 2020518013A JP 7242650 B2 JP7242650 B2 JP 7242650B2
Authority
JP
Japan
Prior art keywords
polypeptide
human
chimeric
nucleic acid
rodent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020518013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535815A5 (cg-RX-API-DMAC7.html
JP2020535815A (ja
Inventor
ブリンダ プラサド,
ナシン トゥ,
カロリーナ ミーガー,
リン マクドナルド,
アンドリュー マーフィー,
ショーン スティーブンス,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020535815A publication Critical patent/JP2020535815A/ja
Publication of JP2020535815A5 publication Critical patent/JP2020535815A5/ja
Priority to JP2023035499A priority Critical patent/JP7534465B2/ja
Application granted granted Critical
Publication of JP7242650B2 publication Critical patent/JP7242650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020518013A 2017-09-29 2018-09-27 ヒト化C1q複合体を発現する非ヒト動物 Active JP7242650B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023035499A JP7534465B2 (ja) 2017-09-29 2023-03-08 ヒト化C1q複合体を発現する非ヒト動物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565438P 2017-09-29 2017-09-29
US62/565,438 2017-09-29
PCT/US2018/053099 WO2019067706A1 (en) 2017-09-29 2018-09-27 NON-HUMAN ANIMALS EXPRESSING A HUMANIZED C1Q COMPLEX

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023035499A Division JP7534465B2 (ja) 2017-09-29 2023-03-08 ヒト化C1q複合体を発現する非ヒト動物

Publications (3)

Publication Number Publication Date
JP2020535815A JP2020535815A (ja) 2020-12-10
JP2020535815A5 JP2020535815A5 (cg-RX-API-DMAC7.html) 2021-11-04
JP7242650B2 true JP7242650B2 (ja) 2023-03-20

Family

ID=63858187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020518013A Active JP7242650B2 (ja) 2017-09-29 2018-09-27 ヒト化C1q複合体を発現する非ヒト動物
JP2023035499A Active JP7534465B2 (ja) 2017-09-29 2023-03-08 ヒト化C1q複合体を発現する非ヒト動物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023035499A Active JP7534465B2 (ja) 2017-09-29 2023-03-08 ヒト化C1q複合体を発現する非ヒト動物

Country Status (18)

Country Link
US (2) US11186848B2 (cg-RX-API-DMAC7.html)
EP (2) EP4249502A3 (cg-RX-API-DMAC7.html)
JP (2) JP7242650B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240128129A (cg-RX-API-DMAC7.html)
CN (2) CN116376973A (cg-RX-API-DMAC7.html)
AU (1) AU2018341685A1 (cg-RX-API-DMAC7.html)
CA (1) CA3077418A1 (cg-RX-API-DMAC7.html)
DK (1) DK3687287T5 (cg-RX-API-DMAC7.html)
ES (1) ES2961713T3 (cg-RX-API-DMAC7.html)
FI (1) FI3687287T3 (cg-RX-API-DMAC7.html)
IL (1) IL273588A (cg-RX-API-DMAC7.html)
LT (1) LT3687287T (cg-RX-API-DMAC7.html)
PT (1) PT3687287T (cg-RX-API-DMAC7.html)
RU (1) RU2020112751A (cg-RX-API-DMAC7.html)
SG (1) SG11202002002XA (cg-RX-API-DMAC7.html)
SI (1) SI3687287T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019067706A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001389B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082546A1 (en) * 1996-11-06 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1407017T3 (en) * 2000-11-07 2009-09-21 Zymogenetics Inc Human receptor for tumor nekrose faktor
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
GB0322998D0 (en) * 2003-10-01 2003-11-05 Ares Trading Sa Protein
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
CN101330925A (zh) * 2005-12-16 2008-12-24 瑞泽恩制药公司 用d114拮抗剂抑制肿瘤生长的治疗方法
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
PL3248462T3 (pl) * 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
CN103380145B (zh) * 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
US9043996B2 (en) * 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
KR102295746B1 (ko) * 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
US9801362B2 (en) * 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
FR2996561B1 (fr) * 2012-10-09 2016-03-18 Commissariat Energie Atomique Procede de preparation de proteine c1q recombinante
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
SG11201510316UA (en) * 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
MX2016014504A (es) * 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
BR112017010793A2 (pt) * 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Acta Neuropathol.,2013年,125(6),829-840
Mol Immunol.,2008年,45(11),3244-3252

Also Published As

Publication number Publication date
DK3687287T3 (da) 2023-10-16
CN116376973A (zh) 2023-07-04
CN111386039A (zh) 2020-07-07
IL273588A (en) 2020-05-31
AU2018341685A1 (en) 2020-04-02
PT3687287T (pt) 2023-11-03
RU2020112751A (ru) 2021-10-29
SI3687287T1 (sl) 2023-11-30
ZA202001389B (en) 2024-01-31
EP4249502A3 (en) 2023-12-06
FI3687287T3 (fi) 2023-10-12
EP3687287A1 (en) 2020-08-05
RU2020112751A3 (cg-RX-API-DMAC7.html) 2022-02-09
DK3687287T5 (da) 2024-08-26
CN111386039B (zh) 2023-02-28
WO2019067706A1 (en) 2019-04-04
EP3687287B1 (en) 2023-07-12
US20220033847A1 (en) 2022-02-03
KR102696334B1 (ko) 2024-08-21
CA3077418A1 (en) 2019-04-04
KR20200058487A (ko) 2020-05-27
EP4249502A2 (en) 2023-09-27
US20190100772A1 (en) 2019-04-04
LT3687287T (lt) 2023-10-25
KR20240128129A (ko) 2024-08-23
JP2023075230A (ja) 2023-05-30
WO2019067706A4 (en) 2019-05-23
ES2961713T3 (es) 2024-03-13
SG11202002002XA (en) 2020-04-29
JP2020535815A (ja) 2020-12-10
JP7534465B2 (ja) 2024-08-14
US11186848B2 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
AU2022202578B2 (en) Non-human animals expressing humanized cd3 complex
US20230225301A1 (en) Vivo Method for Generating Diversity in a Protein Scaffold
JP7534465B2 (ja) ヒト化C1q複合体を発現する非ヒト動物
US20240423176A1 (en) Full-length human ace2 mouse model susceptible to emerging coronaviruses
KR20230004472A (ko) 인간화 cxcl13 유전자를 갖는 비인간 동물
HK40091185A (en) Rodents expressing humanized c1q complex
HK40025141B (en) Rodents expressing humanized c1q complex
HK40025141A (en) Rodents expressing humanized c1q complex

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230308

R150 Certificate of patent or registration of utility model

Ref document number: 7242650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150